Ad is loading...
MDGL
Price
$348.42
Change
+$19.18 (+5.83%)
Updated
Nov 22, 03:29 PM (EDT)
96 days until earnings call
SLS
Price
$1.21
Change
-$0.01 (-0.82%)
Updated
Nov 22, 03:36 PM (EDT)
118 days until earnings call
Ad is loading...

MDGL vs SLS

Header iconMDGL vs SLS Comparison
Open Charts MDGL vs SLSBanner chart's image
Madrigal Pharmaceuticals
Price$348.42
Change+$19.18 (+5.83%)
Volume$100
CapitalizationN/A
SELLAS Life Sciences Group
Price$1.21
Change-$0.01 (-0.82%)
Volume$500
CapitalizationN/A
MDGL vs SLS Comparison Chart
Loading...
MDGL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SLS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
MDGL vs. SLS commentary
Nov 22, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDGL is a StrongBuy and SLS is a StrongSell.

COMPARISON
Comparison
Nov 22, 2024
Stock price -- (MDGL: $329.24 vs. SLS: $1.22)
Brand notoriety: MDGL and SLS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MDGL: 96% vs. SLS: 120%
Market capitalization -- MDGL: $6.92B vs. SLS: $85.87M
MDGL [@Biotechnology] is valued at $6.92B. SLS’s [@Biotechnology] market capitalization is $85.87M. The market cap for tickers in the [@Biotechnology] industry ranges from $463.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.63B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MDGL’s FA Score shows that 1 FA rating(s) are green whileSLS’s FA Score has 0 green FA rating(s).

  • MDGL’s FA Score: 1 green, 4 red.
  • SLS’s FA Score: 0 green, 5 red.
According to our system of comparison, MDGL is a better buy in the long-term than SLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDGL’s TA Score shows that 5 TA indicator(s) are bullish while SLS’s TA Score has 5 bullish TA indicator(s).

  • MDGL’s TA Score: 5 bullish, 6 bearish.
  • SLS’s TA Score: 5 bullish, 6 bearish.
According to our system of comparison, both MDGL and SLS are a bad buy in the short-term.

Price Growth

MDGL (@Biotechnology) experienced а +8.78% price change this week, while SLS (@Biotechnology) price change was -3.94% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.14%. For the same industry, the average monthly price growth was -4.98%, and the average quarterly price growth was +4.01%.

Reported Earning Dates

MDGL is expected to report earnings on Feb 26, 2025.

SLS is expected to report earnings on Mar 20, 2025.

Industries' Descriptions

@Biotechnology (+2.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($6.92B) has a higher market cap than SLS($85.9M). MDGL YTD gains are higher at: 42.294 vs. SLS (15.094). SLS has higher annual earnings (EBITDA): -32.77M vs. MDGL (-502.65M). MDGL has more cash in the bank: 999M vs. SLS (21M). SLS has less debt than MDGL: SLS (576K) vs MDGL (119M). MDGL has higher revenues than SLS: MDGL (76.8M) vs SLS (0).
MDGLSLSMDGL / SLS
Capitalization6.92B85.9M8,051%
EBITDA-502.65M-32.77M1,534%
Gain YTD42.29415.094280%
P/E RatioN/AN/A-
Revenue76.8M0-
Total Cash999M21M4,757%
Total Debt119M576K20,660%
FUNDAMENTALS RATINGS
MDGL vs SLS: Fundamental Ratings
MDGL
SLS
OUTLOOK RATING
1..100
2212
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
57
Fair valued
PROFIT vs RISK RATING
1..100
27100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
3653
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
9550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SLS's Valuation (57) in the Biotechnology industry is in the same range as MDGL (69) in the Pharmaceuticals Other industry. This means that SLS’s stock grew similarly to MDGL’s over the last 12 months.

MDGL's Profit vs Risk Rating (27) in the Pharmaceuticals Other industry is significantly better than the same rating for SLS (100) in the Biotechnology industry. This means that MDGL’s stock grew significantly faster than SLS’s over the last 12 months.

MDGL's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as SLS (100) in the Biotechnology industry. This means that MDGL’s stock grew similarly to SLS’s over the last 12 months.

MDGL's Price Growth Rating (36) in the Pharmaceuticals Other industry is in the same range as SLS (53) in the Biotechnology industry. This means that MDGL’s stock grew similarly to SLS’s over the last 12 months.

MDGL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as SLS (100) in the Biotechnology industry. This means that MDGL’s stock grew similarly to SLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MDGLSLS
RSI
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
71%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
87%
MACD
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 11 days ago
85%
Declines
ODDS (%)
Bearish Trend 8 days ago
82%
Bearish Trend 2 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
84%
Aroon
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Ad is loading...
MDGL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SLS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
QQQJ31.370.44
+1.42%
Invesco NASDAQ Next Gen 100 ETF
LEAD69.820.84
+1.22%
Siren DIVCON Leaders Dividend ETF
FLRG35.250.39
+1.12%
Fidelity U.S. Multifactor ETF
ICSH50.56N/A
+0.01%
iShares Ultra Short-Term Bond Active ETF
IWFG49.23N/A
N/A
NYLI Winslow Focused Large Cap Gr ETF

MDGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with VXRT. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then VXRT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDGL
1D Price
Change %
MDGL100%
+3.83%
VXRT - MDGL
61%
Loosely correlated
-1.40%
ALXO - MDGL
56%
Loosely correlated
+6.61%
REPL - MDGL
55%
Loosely correlated
-1.60%
ZNTL - MDGL
51%
Loosely correlated
+1.60%
CGEM - MDGL
50%
Loosely correlated
-2.86%
More

SLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLS has been loosely correlated with FULC. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if SLS jumps, then FULC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLS
1D Price
Change %
SLS100%
-1.61%
FULC - SLS
48%
Loosely correlated
-0.67%
NKTR - SLS
42%
Loosely correlated
+1.00%
SNPX - SLS
34%
Loosely correlated
-3.24%
AXON - SLS
32%
Poorly correlated
+3.52%
MDGL - SLS
30%
Poorly correlated
+3.83%
More